Medicago and Investissement Quebec Agree to a Three Year Extension of its $15.3M Loan
QUEBEC CITY, Feb. 5, 2013 /PRNewswire/ – Medicago Inc. (TSX: MDG; OTCQX:
MDCGF), a biopharmaceutical company focused on developing highly
effective and competitive vaccines based on proprietary manufacturing
technologies and Virus-Like Particles (VLPs), announced today that
Investissement QuÃ©bec has agreed to a three year extension of the
maturity date of its 2003 loan made under the BioLevier program.
Originally, the maturity date of the loan in the principal amount of
$15.3M, was December 31, 2014 and is now December 31, 2017. Under this
new agreement, Medicago will be required to make minimum annual
re-payments of $1,750,000, $2,500,000, and $2,500,000 in 2014, 2105 and
2016 respectively, with the remaining balance due on December 31, 2017.
The annual interest rate remains 6.75%.
“We are very pleased to see the continued investment support and
commitment of Investissement QuÃ©bec towards Medicago,” said Pierre
Labbe, Vice President and Chief Financial Officer of Medicago. “The
extension of the maturity date of this loan will allow us to maintain a
strong balance sheet as we meet our near term milestones with the
advancement and commercialization of our rapid plant based VLP
As a consideration to Investissement QuÃ©bec for the extention of the
loan, Medicago has granted to Investissement QuÃ©bec, subject to
regulatory approvals, 1,225,492 common share subscription warrants
which may be exercised at a price of $0.50 until December 31, 2018.
Medicago’s pipeline includes:
-- The initiation of a U.S. Phase IIa clinical trial for a quadrivalent seasonal flu vaccine with interim data expected in summer of 2013; -- Phase I clinical trial for an H5N1 VLP vaccine with a new adjuvant that is ongoing in partnership with the Infectious Disease Research Institute (IDRI). Interim data are expected in the first quarter of 2013; -- Newclinical trial of the H5N1 VLP vaccine designed to determine the lowest possible dose by two different administration routes (IM and ID) and combining the vaccine with a GLA adjuvant is planned to start in spring of 2013, with interim data expected in summer of 2013; -- GMP process development and a GLP toxicology study for a rabies vaccine are ongoing; -- Medicago is also working with Mitsubishi Tanabe Pharma under a strategic alliance to develop a vaccine for rotavirus and at least two additional vaccine candidates; -- In addition to vaccines, Medicago is conducting research and development in the area of biosimilar products.
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.
Forward Looking Statements
This news release includes certain forward-looking statements or
forward-looking information for the purposes of applicable securities
laws and such statements and information are based upon current
expectations, which involve risks and uncertainties associated with
Medicago’s business and the environment in which the business operates.
Any statements contained herein that are not statements of historical
facts may be deemed to be forward-looking, including those identified
by the expressions “anticipate”, “believe”, “plan”, “estimate”,
“expect”, “intend”, and similar expressions to the extent they relate
to Medicago or its management. The forward-looking statements are not
historical facts, but reflect Medicago’s current expectations regarding
future results or events. These forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations, including the
matters discussed under “Risk Factors and Uncertainties” in Medicago’s
Annual Information Form filed on March 29, 2012, with the regulatory
authorities. Medicago assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those reflected in the forward-looking statements.
SOURCE Medicago Inc.